Market closed
Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
47,000
Website
Eli Lilly Metrics
BasicAdvanced
$738B
70.17
$11.71
0.34
$5.40
0.73%
Price and volume
Market cap
$738B
Beta
0.34
52-week high
$972.53
52-week low
$711.40
Average daily volume
3.5M
Dividend rate
$5.40
Financial strength
Current ratio
1.154
Quick ratio
0.577
Long term debt to equity
207.516
Total debt to equity
244.616
Dividend payout ratio (TTM)
44.20%
Interest coverage (TTM)
28.15%
Management effectiveness
Return on assets (TTM)
15.33%
Return on equity (TTM)
84.26%
Valuation
Price to earnings (TTM)
70.168
Price to revenue (TTM)
16.429
Price to book
51.96
Price to tangible book (TTM)
326.97
Price to free cash flow (TTM)
728.634
Dividend yield (TTM)
0.66%
Forward dividend yield
0.73%
Growth
Revenue change (TTM)
32.00%
Earnings per share change (TTM)
101.90%
3-year revenue growth (CAGR)
16.73%
3-year earnings per share growth (CAGR)
24.15%
3-year dividend per share growth (CAGR)
15.21%
What the Analysts think about Eli Lilly
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Eli Lilly Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Eli Lilly News
AllArticlesVideos
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
Benzinga·12 hours ago
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
CNBC Television·12 hours ago
Here's one healthcare name this strategist says is buy, and another to avoid
Yahoo Finance·13 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $738B as of March 29, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 70.17 as of March 29, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of March 29, 2025, the dividend rate is $5.4 and the yield is 0.73%. Eli Lilly has a payout ratio of 44.2% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment date is unconfirmed.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.